Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 8/20 | 0.43 |
| ▸ | EGFR | P00533 | 6/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.39 |
| ▸ | MET | P08581 | 2/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | FECH | P22830 | 1/20 | 0.38 |
| ▸ | MYH14 | Q7Z406 | 1/20 | 0.38 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24167945 | 0.86 | ERBB2 (0.51) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL30050202 | 0.85 | EGLN2 (0.37) | ERBB2EGFREGLN2METNQO2 | |
| SCHEMBL30527734 | 0.78 | ERBB2 (0.53) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL24167683 | 0.78 | ERBB2 (0.53) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL105737 | 0.78 | KDR (0.42) | METKDRFLT1CYP17A1BRAF | |
| SCHEMBL107558 | 0.77 | MET (0.48) | METKDRFLT1CYP17A1BRAF | |
| SCHEMBL22525244 | 0.76 | ERBB2 (0.43) | ERBB2EGFRMETNQO2FECH | |
| SCHEMBL29888185 | 0.76 | ERBB2 (0.43) | ERBB2EGFRMETNQO2FECH | |
| SCHEMBL38661795 | 0.76 | EGLN2 (0.45) | EGLN2KDRFLT1CYP17A1 | |
| SCHEMBL24167938 | 0.76 | ERBB2 (0.42) | ERBB2EGFRNQO2FECHMYH14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12447153-B2 | HER2 mutation inhibitors | PFIZER INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20230041385-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2023-02-09 | — | — | US | disclosed |
| WO-2022269531-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041385-A1 | HER2 MUTATION INHIBITORS | ERBB2, EGFR, ERBB3 | ERBB2 1/4885EGFR 2/4885EGLN2 1396/4885 |
| US-12447153-B2 | HER2 mutation inhibitors | ERBB2, EGFR, ERBB3 | ERBB2 1/4885EGFR 2/4885EGLN2 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.